Ultragenyx Pharmaceutical Inc. develops and commercializes therapies for serious rare and ultra-rare genetic diseases. Company news commonly covers revenue from approved medicines such as Crysvita, Dojolvi, and Mepsevii, financial guidance, and updates to a portfolio of approved therapies and product candidates for diseases with high unmet medical need and clear biology.
Recurring developments include FDA interactions and clinical data for investigational programs such as UX111 for Sanfilippo syndrome type A, GTX-102 for Angelman syndrome, UX016 for GNE myopathy, and AAV gene therapy candidates for rare metabolic disorders. Updates also include healthcare conference participation, employment inducement equity grants under Nasdaq rules, and corporate restructuring or expense-management actions when disclosed.
Ultragenyx Pharmaceutical (NASDAQ: RARE) entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The company received the voucher upon FDA approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for glycogen storage disease type Ia.
Ultragenyx said the sale would provide non-dilutive capital to advance rare-disease therapies and support its path to profitability. Closing remains subject to conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Ultragenyx (RARE) announced EMA validation of its marketing authorisation application for investigational gene therapy rebisufligene etisparvovec to treat Sanfilippo syndrome Type A.
Validation establishes that the application is complete enough for formal scientific review; it is not approval or a determination of safety or efficacy. The therapy has received PRIME and Orphan Drug designations, which support development and evaluation without guaranteeing authorisation. The application will fall under the EU Joint Clinical Assessment framework, a coordinated clinical assessment process across member states. Ultragenyx plans geographic expansion and has initiated regulatory engagement with the UK’s MHRA and Saudi Arabia’s SFDA.
Ultragenyx (RARE) received standard full FDA approval for FAYUVI™ (rebisufligene etisparvovec-hopf, UX111) on September 17, 2026 as the first-ever treatment for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A) with preserved neurodevelopmental function.
FAYUVI is a single-dose intravenous AAV9 gene therapy designed to deliver a functional SGSH gene to address the underlying enzyme deficiency. Approval is based on the pivotal Transpher A trial and long-term follow-up (up to nearly 8 years), where treated patients in the modified intention-to-treat group (N=17) showed a 23.5-point higher Bayley-III Cognitive raw score versus an external natural history cohort (N=27; p<0.0001), along with sustained reductions in CSF heparan sulfate.
Ultragenyx expects commercial product availability to ship to a network of U.S. Qualified Treatment Centers within 30–60 days and received a Priority Review Voucher. Key risks include liver enzyme elevations, thrombocytopenia, infusion reactions, and a potential malignancy risk associated with AAV vector DNA integration.
Ultragenyx (RARE) reported topline results from the Phase 3 Aspire trial of apazunersen (GTX-102) in Angelman syndrome, which did not meet its primary endpoint of change from baseline in Bayley-4 cognitive raw score or the key secondary endpoint of net response in the Multidomain Responder Index (MDRI).
The randomized groups were comparable at baseline and no efficacy differences were observed between treated and control groups on Bayley cognition scores or MDRI, including the five individual MDRI components. The safety profile in Aspire was consistent with the earlier Phase 1/2 program. Ultragenyx plans to evaluate the future of the apazunersen program and will reassess its planned operations to implement significant expense reductions while continuing to support its growing commercial business, including the recently approved GENGLYCOS for glycogen storage disease type Ia and the potential approval of UX111 for Sanfillipo syndrome, with a stated goal of achieving profitability in 2027.
Ultragenyx (NASDAQ: RARE) reported 96-week results from its Phase 3 GlucoGene trial of GENGLYCOS (DTX401) AAV gene therapy for glycogen storage disease type Ia (GSDIa), now FDA-approved for patients ≥8 years. At Week 96, both the original DTX401 (n=20) and crossover (n=19) groups showed a mean 61% reduction in daily cornstarch intake from baseline while maintaining glycemic control, with 67–72% of participants achieving ≥50% reduction. One-third of original DTX401 and 42% of crossover participants completely eliminated nighttime cornstarch dosing by Week 96, without increased severe hypoglycemia. Patient-reported outcomes showed 83% of DTX401-treated participants at Week 48 met or exceeded their own pre-defined meaningful reduction threshold, and up to 95% reported overall improvement at Week 96. GENGLYCOS was generally described as having an acceptable, manageable safety profile through Week 96, with transient liver enzyme elevations and hypertriglyceridemia among common adverse reactions, and no observed AAV8 class effects such as dorsal root ganglion toxicity, malignancy, or thrombotic microangiopathy.
Ultragenyx (NASDAQ: RARE) granted 45,984 restricted stock units of common stock to 23 newly hired non-executive officers. The awards were approved by the compensation committee under the Ultragenyx Employment Inducement Plan and granted on August 16, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to continued employment.
Ultragenyx (NASDAQ: RARE) announced that the U.S. FDA has granted accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients ≥8 years with glycogen storage disease type Ia (GSDIa). GENGLYCOS is the first FDA‑approved treatment designed to address the underlying cause of GSDIa and Ultragenyx’s first approved gene therapy, and it reduces daily cornstarch intake as an adjunct to nutritional management. Approval is based on the 48‑week randomized, double‑blind, placebo‑controlled Phase 3 GlucoGene study in 46 participants, in which DTX401 significantly reduced cornstarch requirements versus placebo (p<0.001). Continued approval may depend on verification of clinical benefit through a post‑marketing program including 2‑year data from 50 commercial patients and 20 controls and long‑term follow‑up via the GSDIa Disease Monitoring Program for up to 10 years. Ultragenyx also received a Priority Review Voucher and will supply GENGLYCOS via Qualified Treatment Centers, with in‑house manufacturing at its Bedford, Massachusetts facility and patient support through the UltraCare program.
Ultragenyx (NASDAQ: RARE) reported second quarter 2026 total revenue of $214 million, up from $167 million a year ago, led by Crysvita revenue of $156 million and Dojolvi revenue of $27 million. Evkeeza contributed $21 million and Mepsevii $10 million.
According to Ultragenyx, net loss narrowed to $92 million, or $0.90 per share, versus a $115 million loss, or $1.17 per share, in Q2 2025. Total operating expenses were $289 million, including $34 million of non‑cash stock-based compensation.
The company reaffirmed 2026 guidance for total revenue of $730–$760 million, Crysvita revenue of $500–$520 million, and Dojolvi revenue of $100–$110 million, and expects combined R&D and SG&A expenses in 2026 to be flat to down low-single digits versus 2025 and to decrease by at least 15% in 2027, supporting its stated path to profitability in 2027.
Ultragenyx highlighted near‑term catalysts including two FDA PDUFA action dates for DTX401 (August 23, 2026) and UX111 (September 19, 2026), and Phase 3 GTX‑102 Aspire data for Angelman syndrome expected in September or October 2026. As of June 30, 2026, cash, cash equivalents, and marketable securities were $436 million, with net cash used in operations of $97 million in the quarter.
Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Tuesday, August 4, 2026, to review its financial results and corporate update for the quarter ended June 30, 2026. A live and replay webcast will be accessible via the company’s investor relations website, with the replay available for three months.
Ultragenyx (NASDAQ: RARE) granted 65,886 restricted stock units (RSUs) of its common stock to 39 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan. The RSUs, granted on July 16, 2026, vest over four years at 25% per year, subject to continued employment.